Tlwm Acquires Shares of 16,103 AstraZeneca PLC (NASDAQ:AZN)

Tlwm purchased a new position in AstraZeneca PLC (NASDAQ:AZN) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 16,103 shares of the company’s stock, valued at approximately $1,091,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Anchor Investment Management LLC acquired a new stake in shares of AstraZeneca in the 4th quarter worth about $26,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $27,000. Able Wealth Management LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $27,000. Pin Oak Investment Advisors Inc. grew its holdings in AstraZeneca by 468.4% in the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after buying an additional 370 shares in the last quarter. Finally, Northwest Financial Advisors acquired a new stake in AstraZeneca in the 4th quarter valued at approximately $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AZN. BMO Capital Markets increased their price target on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday. Argus increased their price target on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Finally, Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, AstraZeneca has a consensus rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Stock Performance

AZN traded down $0.90 on Thursday, hitting $78.18. The company had a trading volume of 2,796,709 shares, compared to its average volume of 5,608,135. The stock has a market cap of $242.40 billion, a price-to-earnings ratio of 38.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.48. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.89 and a quick ratio of 0.70. The company’s fifty day moving average price is $77.14 and its 200 day moving average price is $70.20. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $80.86.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.08. The business had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. Equities analysts predict that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.